Skip to content

A randomized controlled trial of esketamine combined with sufentanil on postoperative rebound pain following single shot nerve block

A randomized controlled trial of esketamine combined with sufentanil for rebound pain following single nerve block on postoperative analgesia

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100043633
Enrollment
Unknown
Registered
2021-02-23
Start date
2021-03-01
Completion date
Unknown
Last updated
2021-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rebound pain

Interventions

Group 2:sulfentani PCIA
Group 1:esketamine combined with sulfentanil PCIA

Sponsors

Jinshan Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1)The patients were undergoing open reduction and internal fixationroutine after bone fracture; 2) 18-70 years of age; The American Society of Anesthesiologists (ASA) classification I-II; 3) Willing to cooperate and signed the informed consent

Exclusion criteria

Exclusion criteria: 1) Peripheral nerve injury or lesion; 2) Diabetic peripheral neuropathy; 3) Long-term use of painkillers or alcoholics; 4) Severe complex trauma; 5) Pregnancy; 6) Unstable angina pectoris or myocardial infarction occurred within the past six months;Severe angina pectoris is known from previous illnesses;Congestive heart failure; 7) Severe mental disorders; 8) High intraocular pressure (glaucoma) and penetrating ocular trauma; 9) Other situations in which the combination with esketamine is contraindicated.

Design outcomes

Primary

MeasureTime frame
rebound pain;

Secondary

MeasureTime frame
sleep quality on the day of surgery;NRS pain score;time of first press, numbers of press, percentage of invalid press and total comsumption of sulfentanil on 48h after the surgery;

Countries

China

Contacts

Public ContactJiahui Chen

Jinshan Hospital, Fudan University

1340796725@qq.com+86 18918727380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026